

Claudio Rapezzi is Full Professor of Cardiology at University of Ferrara, Italy. After receiving his MD degree and postgraduate specialization in Cardiovascular Diseases from the University of Bologna, Italy, he worked as Staff cardiologist and Senior Staff cardiologist at the S.Orsola-Malpighi Hospital of Bologna, then becoming Director of the Cardiovascular and Thoracic Department (2008-2013) and Head of the Cardiology Division (2013-2019). Associate Professor of Cardiology since 2001, he held the role of Director of the School of Cardiovascular Diseases at the University of Bologna from 2013 to 2016.

He is currently Full Professor of Cardiology at University of Ferrara and Chief of the Cardiovascular Department of Maria Cecilia Hospital- GVM Research & Care, Cotignola, Ravenna. His clinical, teaching and research activities are mainly focused on heart failure (especially its pathophysiology and medical therapy), cardiomyopathies (and particularly cardiac amyloidosis and genetic cardiomyopathies), acute and chronic ischemic heart diseases, aortic diseases.

He is member of the Italian Society of Cardiology and Fellow of the European Society of Cardiology (ESC), member of the Council on Cardiovascular Genomics, previous Member of the Training Committee of the ESC, and Member of the Task Force for the Guidelines on Diagnosis and Treatment of Hypertrophic Cardiomyopathy, Member of the Executive Committee of the THAOS Registry and Past Nucleus Member of the Working Group on Myocardial and Pericardial Diseases of the ESC. He has been one of the leading authors of the recently published position paper on the diagnosis and management of cardiac amyloidosis promoted by the ESC.

He is author of more than 465 original publications on national and international peer-reviewed journals, with an H-index of 61 and more than 27340 citations. He is member of the editorial board of Italian Journal of Cardiology, Minerva Cardiology and Angiology, Eur Heart J Suppl, and former editor of SIC et Simpliciter (Official Journal of the Italian Society of Cardiology). He serves as peer reviewer for the most renowned medical and cardiovascular journals, including the British Medical Journal, the New England Journal of Medicine, the European Heart Journal, the Journal of the American College of Cardiology, JACC Imaging, Circulation, Heart, the International Journal of Cardiology, Amyloid, Chest, Cardiology, Europace, the Journal of Cardiovascular Medicine.


He has served as Principal Investigator and Steering Committee member for several international RCTs, and has recently co-chaired the ATTR-ACT trial. He has received research grants from several institutions and drug companies.

## **DISCLOSURES**

Research grants (institutional) from Pfizer

Board participation and speaker fees from Pfizer, Sanofi, Alnylam, Novartis.

Ferrara May 7<sup>th</sup>, 2022



Claudio Rapezzi